key: cord-1020150-lqwpr1wy authors: Gangnus, Tanja; Burckhardt, Bjoern B. title: Reliable measurement of plasma kinin peptides: Importance of preanalytical variables date: 2022-01-12 journal: Res Pract Thromb Haemost DOI: 10.1002/rth2.12646 sha: 8e113fc952b51a97691a1fcf152b3a5996a37e52 doc_id: 1020150 cord_uid: lqwpr1wy BACKGROUND: The kallikrein‐kinin system is involved in many (patho)physiological processes and kinin peptides are considered potential clinical biomarkers. Variance in blood specimen collection and processing, artificial ex vivo bradykinin formation, and rapid degradation of kinins have contributed to divergence in published plasma levels, therefore limiting their significance. Thus, reliable preanalytical settings are highly required. OBJECTIVES: This study aimed to develop and evaluate a standardized preanalytical procedure for reliable kinin quantification. The procedure was based on identification of the most impactful variables on ex vivo plasma level alterations. METHODS: Suitable protease inhibitors and blood specimen collection and handling conditions were systematically investigated. Their influence on plasma levels of seven kinins was monitored using an established in‐house liquid chromatography–tandem mass spectrometry platform. RESULTS: In nonstandardized settings, ex vivo rise of bradykinin was found to already occur 30 seconds after blood sampling with high interindividual variation. The screening of 17 protease inhibitors resulted in a customized seven‐component protease inhibitor, which efficiently stabilized ex vivo kinin levels. The reliability of kinin levels was substantially jeopardized by prolonged rest time until centrifugation, phlebotomy methodology (eg, straight needles, catheters), vacuum sampling technique, or any time delays during venipuncture. The subsequently developed standardized procedure was applied to healthy volunteers and proved it significantly limited interday and interindividual kinin level variability. CONCLUSION: The developed procedure for blood specimen collection and handling is feasible in clinical settings and allows for determination of reliable kinin levels. It may contribute to further elucidating the role of the kallikrein‐kinin system in diseases like angioedema, sepsis, or coronavirus disease 2019. • Current divergency of published plasma kinin levels impede the significance of studies. • Here, impactful preanalytical variables regarding reliable kinin quantitation were identified. • A standardized procedure was developed that was proven to limit interday and interindividual variability. • Applicability in clinical settings facilitates study of kinins in, for example, angioedema or sepsis. The kallikrein-kinin system (KKS) is an endogenous cascade of several bioactive kinin peptides that promote vasodilation, diuresis, inflammation, vascular permeability, and angiogenesis. 1 Thus, kinins are considered potential biomarkers in disorders like coronavirus disease 2019 (COVID- 19) , cancer, sepsis, or angioedema. [2] [3] [4] However, bioanalysis of endogenous kinin levels is highly sensitive to artificial alterations hindering their reliable quantification and interpretation of study results. These alterations in the KKS intertwine closely with the intrinsic coagulation cascade, whereby contact between blood and either pathophysiologic (eg, neutrophil extracellular traps, long-chain polyphosphates) or artificial (eg, glass) surfaces initiates autoactivation of factor XII (FXII). 5 Activated FXII (FXIIa) can liberate bradykinin (BK) from high-molecular-weight kininogen after activating prekallikrein to plasma kallikrein (PKa). For bioanalysis, this process of so-called contact activation increases the risk of inaccurate results. It is well established that preanalytical variables considerably impact the sample quality and reliability of results, with reported rates between 32% and 75%. 6, 7 Bioanalytical assays related to the coagulation system, particularly peptide analysis, are most prone to variations caused by inadequate specimen handling. 8, 9 Insufficient control of contact activation during blood sampling and processing introduces a potential source of error in kinin quantitation. 5 Additionally, BK and kallidin (KBK) have short half-lives (<1 minute). 10 Thus, inadequate phlebotomy conditions and downstream processes may alter kinin levels artificially, impeding reliable bioanalysis. Published approaches to determining kinins vary regarding the protease inhibitor used, and reporting on preanalytical variables is limited. [11] [12] [13] [14] Consequently, results have yielded diverging levels of BK, ranging from low picograms-per-milliliter to high nanogramsper-milliliter levels in healthy volunteers. 12, 13, [15] [16] [17] Even in healthy individuals, this large variability hinders the comparison and interpretation of study results. 18 Some research groups have therefore focused on measuring the more stable (half-life ≈ 90 minutes) but inactive metabolite BK- (1) (2) (3) (4) (5) only, which is less prone to artificial changes. 11, 19 However, monitoring only individual kinin levels renders the profiles of kinin level alterations within the KKS in pathophysiological processes incomplete. The versatility of metabolic processes and the numerous active kinins within the KKS highlight this lack of comprehensive evidence. Recently, optimization of mass spectrometric sensitivity of kinins enabled the detection of several kinin peptides simultaneously. 20,21 However, despite a capable protease inhibitor stabilizing kinins, 22 kinin level variability persisted in preliminary experiments, signifying the influence of additional preanalytical variables. Therefore, this study aimed to enable robust kinin quantification in plasma by first identifying critical preanalytical variables contributing to artificial changes in plasma kinin levels. Therefore, plasma levels of the kinins BK, KBK, BK-(1-8), KBK-(1-8), BK-(1-7), BK-(2-9) and BK-(1-5) were monitored using mass spectrometry. Subsequently, this study sought to develop a standardized procedure combining the findings from preanalytical blood specimen collection and handling and appropriate inhibition of kinin formation and degradation. Fresh blood samples were collected from healthy adult volunteers. The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Medical Faculty at Heinrich-Heine University (study no. 6112). All participants gave their written informed consent before enrollment. Figure 1 provides an overview of the investigated preanalytical variables and the general workflow in the following sections. Initially, the extent of artificial kinin formation via contact activation in a routine blood collection without protease inhibition was assessed (n = 4). Blood was collected freshly into EDTA (1.6 mg/mL S-Monovettes (Sarstedt, Nümbrecht, Germany), centrifuged, and immediately analyzed within 30 minutes. Additionally, ex vivo formation and degradation of BK and its metabolites in freshly collected blood samples (EDTA and citrate) were monitored over time to investigate the latency of this process. At predefined time points after blood sampling, a customized protease inhibitor 22 was added to whole-blood aliquots to stop reactions (15, 30, 45 , 60, 90, 120, 180, 240, and 300 seconds; and 10, 15, and F I G U R E 1 Overview of the conducted investigation regarding the preanalytical variables. The preanalytical conditions were optimized step by step based on the results of the previous step (top-down). The general workflow was consistent for all experiments, including fresh blood samples and direct analysis without long-term storage. LC-MS/MS, liquid chromatography-tandem mass spectrometry F I G U R E 2 Addressed targets by the customized protease inhibitor within the kallikrein-kinin system (A). Targets were assigned based on known characteristics of inhibitors. The kininases involved in kinin metabolism are shown with their catalytic type and cleavage site in (B). BK, bradykinin; FA, formic acid; FXIIa, activated factor XII; HDMB, hexadimethrine bromide; HK, high-molecular-weight kininogen; KBK, kallidin; LK, low-molecular-weight kininogen; PKa, plasma kallikrein, TK, tissue kallikrein 30 minutes). Next, whole blood was centrifuged and plasma was analyzed directly. Although the final composition of the protease inhibitor has already been published, 22 The developed inhibitor's performance was evaluated through comparison against commercially available inhibitors and samples without any protease inhibitors. BD P100 and P800 blood collection tubes (Becton Dickinson [BD], Heidelberg, Germany) were applied. These tubes are precoated with BD's proprietary protease inhibitors (unknown exact composition) and designed to minimize preanalytical variability for protein analysis. Blood was freshly drawn into respective tubes prespiked with kinins (1 ng/mL) to monitor their degradation or formation. Plasma was then analyzed immediately and 3 hours after blood sampling (n = 3). The impact of the blood sampling technique on measured kinin levels was investigated to account for the contact activation-mediated artificial rises of kinin levels. Blood was sampled into EDTA tubes prespiked with the customized protease inhibitor in the upright position. 22 The tubing was prefilled to avoid insufficient filling of the tubes by air volume. Three tubes were drawn sequentially per setting and volunteer to assess kinin level consistency better. In comparing blood collection systems, a distinct peripheral arm vein (left or right median cubital, cephalic, or basilic) was used to avoid impacts of venipuncture or time delays. An interexperimental control was drawn in triplicate using 21G Safety Multifly with 200 mm tubing (0.8 × 19 mm) (Sarstedt) and 1.2 mL S-Monovettes (Sarstedt). Blood samples were centrifuged immediately after collection, and plasma was then analyzed. In clinical blood collection settings, blood processing and centrifugation delays often occur (e.g. unavailability of centrifuges on the ward). During this dwell-time increased metabolic activities via additional proteolytic enzymes located on cells 24-26 may alter peptide metabolism, affecting the reliability of results. In assessing this impact on kinin levels, whole blood was sampled freshly into tubes containing the customized protease inhibitor and 1 ng/mL of kinins. Subsequently, the blood was centrifuged immediately (reference [≈ 30 minutes]), 75 and 110 minutes after blood sampling, and stability was analyzed (n = 3). For each centrifugation protocol, spiked kinin peptides in a concentration of 150 pg/mL (n = 3) were evaluated. Three centrifugation methods were applied at 21°C. First, the laboratory's standard protocol of single centrifugation at 2,000 g for 10 minutes was used; second, single centrifugation at 2,000 g for 20 minutes; and third, two-step centrifugation at 2,000 g for 10 minutes followed by 16,100 g for 10 minutes. Additionally, whole blood was sampled on ice and centrifuged at 2,000 g for 10 minutes at 4°C to assess temperature influence. A standardized procedure for kinin collection, processing, and quantification was developed on the basis of identified impactful preanalytical variables. In determining the reliability of optimized preanalytical conditions, the repeatability of sampling was assessed. Based on the findings presented, the following standardized procedure was applied: Venous blood was collected in an antegrade fashion into three consecutive 1.2 mL EDTA S-Monovettes prespiked with the customized protease inhibitor using 21G Safety Multifly needles with 200 mm tubing (Sarstedt) under aspiration. Phlebotomy was conducted in the upright position between 11 am and 1 pm using a tourniquet. Samples were centrifuged at 2,000 g for 10 minutes at 21°C. Kinin levels were determined in one female volunteer on five different days (interday variability). In addition, venous blood was collected from seven healthy volunteers (interindividual variability). Table 1 . In proving the validity and collection of high-quality data, a quality control system directed the handling of all measurements. This audited quality control system 28 required processing validation and applicability runs with calibration standards and quality control samples. Before each analysis, a system suitability test ensured accurate and reproducible LC-MS/MS performance. Additionally, an interexperimental control was drawn in triplicate (Section 2.3) to correct for biological variability. Descriptive statistics (mean ± standard deviation [SD] or median [interquartile range]) and box-whisker-plots depicted kinin level data. Outcomes were analyzed using the Mann-Whitney U-test or Levene test for equality of variance. Statistical analyses were performed with the two-sided alternative hypothesis at the 5% significance level. Calculations and graphics were made using OriginPro 2021 (9.8.0.200). To prevent artificial ex vivo BK formation, screening of serine protease inhibitors revealed similar or higher BK levels using aprotinin, PMSF, or AEBSF compared with uninhibited plasma (Figure 4) 27 HDMB, hexadimethrine bromide P800 tubes did not contribute to any substantial improvement (degradation of 41% for BK- [1] [2] [3] [4] [5] [6] [7] up to 100% for KBK), but P800 tubes limited BK formation as far as could be assessed given the spiked concentrations. When comparing blood collection systems, no significant difference was found between the 21G butterfly-winged systems with 80 or 200 mm tubing ( Figure 6C ). However, collection with The altered blood-to-surface ratio due to distinct diameters of S-Monovettes did not compromise kinin levels, when sampled under aspiration ( Figure 6A ). Interestingly, comparing S-Monovettes and Vacutainer tubes revealed differences in kinin levels; the latter showed higher variability in kinin levels (P = .04; Figure 6D ). The resting of blood in the collection device during blood sampling must be avoided, as kinin levels significantly increased for both butterfly (8-fold during 2-minute rest) and peripheral catheter (25-fold during 5-minute rest) sampling (P < .001 and P = .003; Figure 6B ). cated that blood should be collected using the aspiration technique. BK levels differed significantly with vacuum collection using Vacutainers (P = .04). This tendency was also detectable for vacuum collection using S-Monovettes (P = .05) ( Figure 6D ). The evaluation of potential shear forces affected by antegrade or retrograde cannulation showed significantly elevated BK levels when inserted in a retrograde fashion (P = .03). Exogenously added kinins demonstrated increased degradation in whole blood despite using the customized protease inhibitor. In comparing time to centrifugation, centrifugation within 30 minutes resulted in REs ≤15% compared to a fresh standard for all kinins. Delayed centrifugation after 75 and 120 minutes caused a decline of kinin levels (up to −62% for BK- [1] [2] [3] [4] [5] [6] [7] [8] ). BK-(1-5) was the exception; levels increased up to 26% (120 minutes), indicating accumulation of the most stable kinin due to degradation of more short-lived upstream kinins. Additionally, variability between the tubes increased over time. Comparison of centrifugation methods did not yield significant differences (P > .38) in kinin levels. Table 2 The phlebotomy setting severely impacted the reliability and accuracy of kinin levels. For coagulation assays, research has suggested that conventional straight needles were superior to butterfly F I G U R E 6 Impact of blood sampling conditions on kinin levels. Box-whisker-plots show the impact of the tube size (A), time delays (B), collection devices (C) and the collection technique (D). Experiments were carried out at least in triplicate (A: n = 3; B: n = 3 or n = 6, respectively; C: n = 3, n = 6 or n = 9; D: n = 6). An interexperimental control using Safety Multifly needles 21G with 200 mm tubing into 1.2-mL S-Monovettes under aspiration was run for each experiment needles or peripheral catheters due to reduced hemostatic alteration and decreased surface area for contact activation. 35 However, others have found no differences among these three collection systems. 36 it is further recommended to minimize trauma during blood draws, to avoid producing bubbles or foam, and to reduce shear stress. 38 In line, blood sampling in Vacutainers or S-Monovettes under vacuum produced more variable results than blood sampling under aspiration. Consequently, reduction of shear forces and stress on the vessel in addition to rapid sampling facilitated the most consistent kinin level measurements. While the sample collection settings were most crucial in controlling kinin formation, specimen handling was predominantly decisive regarding loss of kinins. Higher availability of degrading enzymes on blood cell surfaces, for example, aminopeptidases or ACE2, presumably limited kinin stability in whole blood (30 minutes) in comparison to plasma (1.5 hours). 21,24-26 Furthermore, reducing nonspecific peptide adsorption during sample handling minimized variability of recovery, particularly in extracted samples due to reduced saturation of protein-binding surfaces. 39 In addition to using protein low-binding tubes, high acidic amounts and organic solvents using polypropylene materials reduced kinin adsorption and contributed to increased method robustness. 20 Finally, using the implemented standardized procedure demonstrated repeatability of measured kinin levels. This study exemplified the limitation of interday and interindividual variability (<1.7 pg/mL). The sample collection and on-ward preparation using the standardized procedure in this study allow for implementation into clinical TA B L E 2 Standardized procedure for preanalytical conditions of kinin quantification Advised procedure The use of suitable protease inhibitors largely influences plasma kinin levels. A mixture of 3 mg/mL hexadimethrine bromide, 19.8 µM nafamostat, 83 mM EDTA, 20 mM citrate, 1% formic acid, 1 µM omapatrilat, and 1 mM chloroquine was found to be effective. 22 Blood collection system Sampling using catheter, Micro-Needle or straight needles jeopardized kinin levels. Butterfly-winged needles with a needle size of 21G are advisable. No major influence if aspiration technique is applicable. Polypropylene tubes with size from 1.2 up to 9 mL possible. Blood collection technique Vacuum sampling and time-delays increased variability of kinin levels. Use the aspiration technique applying a constant move, rapidly perform sampling of blood and avoid any time delays after venipuncture. Whole-blood storage Increased degradation of kinins in whole blood. Centrifuge within 30 min after blood collection. No major influence on kinin levels. Apply 2,000 g for 10 min at 21°C. Box-whisker-plots of the kinin levels for interday (A) and interindividual (B) variability using the developed standardized procedure. Only kinin levels above the lower limit of quantification were shown. N = 3 Handbook of biologically active peptides A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm The kinin-kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers The role of contact system in septic shock: the next target? An overview of the current evidence Bradykinin: inflammatory product of the coagulation system Errors in a stat laboratory: types and frequencies 10 years later Errors in laboratory medicine Preanalytical variables in the coagulation laboratory Influence of blood collection methods and long-term plasma storage on quorumsensing peptide stability Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat Bradykinin analysis revived-a validated method for determination of its stable metabolite in whole blood by LC-MS/MS Kinins in humans Plasma bradykinin in angio-oedema. The Lancet Plasma bradykinin concentrations during septic shock determined by a novel LC-MS/MS assay Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus Antagonizing and measurement: approaches to understanding of hemodynamic effects of kinins Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study Quantification of BK1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid-chromatographic tandem mass spectrometric assay Improving sensitivity for the targeted LC-MS/MS analysis of the peptide bradykinin using a design of experiments approach Targeted LC-MS/MS platform for the comprehensive determination of peptides in the kallikrein-kinin system Stabilization of short-lived peptides of the kallikrein-kinin system in human plasma to facilitate use as promising biomarkers The contact activation and kallikrein/kinin systems: Pathophysiologic and physiologic activities The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation Human monocyte subsets exhibit divergent angiotensin I-converting activity Aminopeptidase P and dipeptidyl peptidase IV activity in human leukocytes and in stimulated lymphocytes Bioanalytical Method Validation: Guidance for Industry A quality control system for ligand-binding assay of plasma renin activity: Proof-ofconcept within a pharmacodynamic study The search for biomarkers in hereditary angioedema Effect of hexadimethrine bromide on plasma kinin formation, hydrolysis of p-Tosyl-L-argnine methyl ester and fibrinolysis Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system Bradykinin peptides in kidney, blood, and other tissues of the rat A kinetic fluorimetric assay for the measurement of angiotensin-converting enzyme in human serum Prolylcarboxypeptidase (angiotensinase C) in human lung and cultured cells Monitoring thrombin generation: is addition of corn trypsin inhibitor needed? Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method No influence of a butterfly device on routine coagulation assays and D-dimer measurement Preanalytical issues in the haemostasis laboratory: guidance for the clinical laboratories Recommendations for the generation, quantification, storage, and handling of peptides used for mass spectrometry-based assays Reliable measurement of plasma kinin peptides: Importance of preanalytical variables routine to further investigate kinins in diseases like angioedema or sepsis. The developed procedure combined with the LC-MS/MS platform 21 enables improved study of diseases related to the KKS, such as COVID-19, angioedema, sepsis, Alzheimer disease, epilepsy, cancer, and strokes. Reliable kinin quantification facilitates investigation of kinin profile alterations in health and disease and therefore may help identify promising new therapeutic targets. The authors thank Prof. Holger Schwender (Mathematics, Heinrich-Heine University Düsseldorf) for his statistical advice for evaluation of the study results. The authors declare no conflicts of interest. TG and BBB designed the concept and performed the experiments.